Peer-influenced content. Sources you trust. No registration required. This is HCN.
Renal & Urology News
“At 10 years, BCF was 38.0% for HDR compared with 10.4% for SBRT.” — Udovicich et al., JAMA Network Open, February 2026
Oncology, Radiation March 17th 2026
“The WOLVERINE meta-analysis provides the strongest evidence to date that MDT improves progression-free survival, radiographic progression-free survival, and castration resistance-free survival.” — Tang et al., The Lancet Oncology
Oncology, Medical February 17th 2026
Annals of Internal Medicine
Despite the scale of prostate-specific antigen (PSA) testing for prostate cancer screening, prediction models do not predict time-to-event end points or adjust for patient life expectancy.
Family Medicine/General Practice February 6th 2026
MedCentral
“The pain may not correlate with the extent of the disease. A patient with severe endometriosis may report little pain while someone with little extent of disease may report much pain.”
Obstetrics & Gynecology January 13th 2026
Cancer Therapy Advisor
Although men in this cohort have a good prognosis, this finding is clinically relevant, as change in PSA is a factor in determining whether men opt to remain on [active surveillance].
Geriatrics November 17th 2025
Cleveland Clinic | Consult QD
“Controlling cancer is, of course, the goal, but there must also be a greater emphasis on life after treatment.”
Obstetrics & Gynecology September 15th 2025
DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS